more effective and safer approaches for reducing the risk of cerebral ischaemic/reperfusion injury during the perioperative period.
Ischaemic preconditioning-induced neuronal tolerance to ischaemia was first reported by Kitagawa and colleagues 3 in 1990. However, ischaemic preconditioning is invasive and impractical for clinical practice. Several groups have found that pharmacological preconditioning methods such as volatile anaesthetics preconditioning can induce ischaemic tolerance in mice and rats. 4 -6 Furthermore, volatile anaesthetic preconditioning has been used in coronary arterial surgery for cardiac protection in a rat model. 7 Volatile anaesthetic preconditioning is a promising strategy for perioperative neuroprotection that is less invasive, and sevoflurane preconditioning has been shown inducing tolerance against cerebral ischaemia insults in animal models. 8 9 However, the underlying mechanisms for its neuroprotective effects are unclear. Two-pore domain background potassium channels (K 2 P) are a diverse and highly regulated superfamily of ion channels that likely modulate membrane excitability in physiological functions. 10 As a subfamily of K 2 P channels, TREK channels are predominantly expressed in the central nervous system. 11 TREK channels can be activated by membrane stretch, temperature, and internal acidosis, and are regulated by various pharmacological agents and cellular lipids, including volatile anaesthetics. Recent studies have suggested that the activation of TREK channels including TREK-1 mediates neuroprotection. 12 Moreover, researchers have demonstrated that TREK-1 plays an essential role for anaesthesia, neuroprotection, depression, and pain. 13 We hypothesized that TREK-1 plays a crucial role in mediating the neuroprotective effect against cerebral ischaemia afforded by sevoflurane preconditioning.
Methods

Animals and cells
All experimental procedures were carried out in accordance with the protocols approved by the Ethics Committee for Animal Experimentation of the Fourth Military Medical University (Xi'an, China) and in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and ARRIVE guidelines. SH-SY5Y cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Adult male Sprague -Dawley rats (280 -320 g) were purchased from the Laboratory Animal Center of our university.
Experimental protocol
Role of TREK-1 in the neuroprotective effect of sevoflurane differentiated SH-SY5Y cells SH-SY5Y human neuroblastoma cells were stimulated by all-trans-retinoic acid (RA) in cell culture for several days to stimulate differentiation into neurone-like cells, as identified by expressions of the neurone markers NeuN and bIII-tubulin. Differentiated cells were then subjected to various treatments. In the OGD group, cells were challenged by oxygen-glucose deprivation (OGD). In the Pre+OGD group, cells were exposed to 3.3 vol% sevoflurane for 2 h, and then after 1 h, they were subjected to OGD. In the siRNA group, small RNA interference (siRNA) was used to inhibit the expression of TREK-1 24 before sevoflurane preconditioning and OGD. In the siRNA-c group, control siRNA served as a reference to judge the effect of siRNA vector. Cells in the normal group were cultured without any treatments. After completion of treatments, cell viability was measured by the 3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyl-tetrazolium bromide (MTT) assay and caspase-3 expression was examined by western blot and immunofluorescence.
Role of TREK-1 in neuroprotection induced by sevoflurane in cerebral ischaemic rats
In order to investigate the effect of sevoflurane preconditioning against ischaemia-reperfusion injury, rats were randomly divided into three groups using an online randomization programme: sham, ischaemia (MCAO), and sevoflurane preconditioning plus ischaemia (Pre+MCAO) groups (n¼8 -9 each). Functional neurological outcomes were observed at 24, 48, 72 h, and 1 week after middle cerebral artery occlusion (MCAO) injury, and cerebral infarct volumes were measured at 72 h and 1 week. In addition, western blot and real-time polymerase chain reaction (PCR) analysis were used to detect levels of TREK-1 protein or in RNA at 4, 24, and 48 h after ischaemia -reperfusion injury in another set of animals.
In order to verify the role of TREK-1 in sevoflurane preconditioning-induced neuroprotection against ischaemia, we created an siRNA construct against TREK-1. The reliability of the siRNA was tested in normal rats before use. To examine the impact of siRNA on the neuroprotective effect of sevoflurane pretreatment, rats were randomly allocated to the following groups: sham, MCAO, sevoflurane preconditioning plus MCAO (Pre+MCAO), TREK siRNA plus sevoflurane preconditioning plus MCAO (siRNA+Pre+MCAO), and control siRNA plus sevoflurane preconditioning plus MCAO (siRNA-c+ Pre+MCAO). The effect of siRNA on functional neurological outcomes was observed at 24, 48, and 72 after ischaemia, and cerebral infarct volume was compared at 72 h after ischaemiareperfusion.
Cell culture and characterization
The human neuroblastoma cell line SH-SY5Y is often stimulated by RA to differentiate into neurone-like cells to model the responses of neurones. 14 
Sevoflurane preconditioning and OGD in vitro
Preconditioning conditions were achieved by incubation of the cells in 3.3 vol% sevoflurane with 5% CO 2 and 95% air for 2 h. 16 17 Cells were then placed in the incubator filled with 5% CO 2 95% air for 1 h before OGD. To induce ischaemic injury, cells were subjected to OGD treatment. Cultures were first washed twice with DMEM without glucose and then put into pre-warmed OGD medium at 378C for 120 min. The OGD buffer containing 154 mM NaCl, 5.4 mM KCl, 0.8 mM MgSO 4 , 1.0 mM NaH 2 PO 4 , 2.3 mM CaCl 2 , and 3.6 mM NaHCO 3 was bubbled with 95% air and 5% CO 2 . OGD was terminated by returning to normal culture medium for an additional 24 h.
RNA interference
TREK-1 siRNA and negative control scrambled siRNAs were designed and purchased from Qiagen (Italy). The target sequence of the TREK1-siRNA used in this study was: 
Cell viability assay
Cell viability was measured by the MTT assay, a mitochondrial enzyme-dependent reaction. Briefly, MTT was added to cells in 96-well plates after completion of the experimental treatments. In metabolically active cells, the yellow tetrazolium MTT salt is cleaved into purple formazan crystals, which can be solubilized and the absorbance measured by a multi-plate reader at 490 nm.
Western blot
To assess the expression of neuronal markers, TREK-1, and apoptotic proteins, cells were seeded into 75 cm 3 cell culture bottles at a density of 5×10 6 , washed with ice-cold phosphatebuffered saline (PBS) twice, and resuspended in RIPA buffer (pH 7.0) containing protease inhibitors (F. Hoffmann-La Roche, Basel, Switzerland). After sonication, 20 mg of total protein extracts was subjected to sodium dodecyl sulphatepolyacrylamide gel electrophoresis and then transferred to a polyvinylidene difluoride membrane. Non-specific binding was blocked in 5% of milk in Tris-buffered saline Tween-20 (TBST) for 1 h, and probed with rabbit anti-beta III tubulin (1:5000, ab6046, Abcam, Cambridge, UK), mouse anti-NeuN (1:5000, MAB377, Millipore, MA, USA), rabbit anti-TREK-1 (1:800, sc-50412, Santa Cruz, CA, USA), or rabbit anti-caspase-3 (1:2000, ab32351, Abcam). After rinsing, membranes were probed with an anti-rabbit or anti-mouse secondary antibody for 2 h at room temperature. To examine the expressions of TREK-1 in the brain, animals were decapitated and the brains rapidly harvested. The ipsilateral forebrain to the ischaemic insult was dissected and homogenized.
Immunofluorescence staining
Cells grown on 22 mm sterilized glass coverslips were fixed with 4% (v/v) paraformaldehyde in PBS for 30 min and then thoroughly rinsed with PBS. Primary antibodies used were rabbit anti-bIII-tubulin (1:500), mouse anti-NeuN (1:2000), rabbit anti-TREK-1 (1:200), and rabbit anti-caspase-3 (1:1000). Subsequently, coverslips were washed with PBS and incubated with secondary antibodies conjugated with fluorescent probes for 2 h at room temperature. Nuclei were counterstained with DAPI. Coverslips were washed and mounted on glass slides with anti-fading medium for observation and analysis. Images were captured by using a Nikon E600 fluorescent microscope (Nikon, Tokyo, Japan).
Rat transient MCAO model
Cerebral ischaemia induced by transient MCAO in rats was performed as described previously. 18 19 After an overnight fast, animals were anaesthetized by 3% sevoflurane for surgery the adequate depth of anaesthesia was ascertained by ensuring lack of response to toe pinch. After the skin of the neck was cut open and the carotid arteries were dissected out, a transient focal cerebral ischaemia model was induced by occlusion of the right middle cerebral artery using intraluminal 3-0 monofilament nylon suture (Ethicon, Inc., Osaka, Japan). After 120 min of ischaemia, the suture was removed from the internal carotid artery carefully. Rats in the sham-operated control group were subjected to the same surgical procedure except that the suture was not inserted. The rescue analgesia protocol included meloxicam i.p. 0.2 mg kg 21 body weight postoperatively on day 1 followed by 0.05 mg kg 21 per day for 3 days.
Sevoflurane preconditioning in vivo
Preconditioning of the rats was achieved by inhalation of 2.7 vol% sevoflurane+97% O 2 for 1 h. 8 The control group rats were treated for the same duration but were allowed to inhale 97% O 2 only. After a washout period of 1 h, rats were subjected to MCAO surgery.
Transfection of siRNA
We tested the reliability of siRNA against TREK-1 in normal rats.
The following target sequence was used:
′ . The sense and antisense sequence of siRNA were 5 ′ -GGCUACGGGUGAUAUCUAATT-3 ′ and 3 ′ -UUAG AUAUCACCCGUAGCCAG-5 ′ , respectively. We carried out in vivo siRNA transfections according to the method of Luo and colleagues. 20 Rats were randomly allocated to five groups: (i) normal (without intervention), (ii) siRNA (TREK-1 siRNA), (iii) siRNA-c (control scrambled siRNA was given), (iv) siRNA+Pre+MCAO (TREK-1 siRNA followed by sevoflurane preconditioning plus MCAO), and (v) siRNA-c+Pre+MCAO (control siRNA followed by sevoflurane preconditioning plus MCAO). Under pentobarbital anaesthesia (40 mg kg
21
, i.p.), a stainless steel guide cannula was stereotactically fixed into the unilateral cerebral ventricle. The stereotaxic coordinate of the lateral cerebral ventricle was 1.0 mm posterior to the bregma and 1.2-1.5 mm lateral to the midsagittal line. 21 A diluted mixture (5 ml) was microinjected into the ipsilateral lateral ventricle. After 24 h, animals were subjected to subsequent treatments.
Real-time PCR analysis for detection of TREK-1 mRNA expression in the brain
Total RNA was extracted from the forebrain using Trizol reagent (Invitrogen Technology) following the manufacturer's protocol. Forward and reverse primer sequences were: TREK-1 TGACCTCA GACAGTCGGTAT/CAAGCCTGCTATACCTCGT, b-actin GTGCCCATCT ATGAGGGTTACGCG/GGAACCGCTCATTGCCGATGTG. Each 20 ml reaction system was mixed with 10 ml SYBR Premix Ex Taq II (2×) (Takara Bio Inc.), 0.8 ml PCR forward primer (10 mm), 0.8 ml PCR reverse primer (10 mm), 0.4 ml ROX Reference Dye (50×) (Takara Bio Inc.), 2 ml complementary DNA (cDNA), and 6 ml RNAase-free water (48C). Conditions of the two-step PCR were as follows: 1 cycle at 958C for 30 s, then 40 cycles at 958C for 5 s, 558C for 15 s, and 728C for 31 s.
TREK-1 mediates sevoflurane neuroprotection
Physiological parameters
As sevoflurane inhalation can induce acute hypoxaemia, it was very necessary to rule out the neuroprotective effect of hypoxia-induced preconditioning. Therefore, blood gases of 10 additional animals were measured during sevoflurane preconditioning (n¼5) or oxygen inhalation (n¼5) in a separate experiment. A cannula (PE 10, Becton Dickinson, Rutherford, NJ, USA) connected to an amplifier was placed in the left femoral artery and attached to invasive arterial pressure monitoring equipment (Spacelabs Medical, Inc., Redmond, WA, USA). Arterial blood gas samples were continuously monitored at the beginning, during, and just before termination of preconditioning. Samples were then measured using the OMNI Modular System (AVL List GmbH Medizintechnik, Graz, Austria).
Since the surgical procedure of the MCAO model is very short (average time for intraluminal suture insertion is 5 min and the removal time is 1-2 min), the physiological parameters were not measured during the surgical procedure according to previous reports. 22 However, a separate experiment was undertaken to measure physiological parameters, which showed no statistically significant differences between the sham and MCAO groups (data not shown). At the end of the study period, all animals were killed using i.p. sodium pentobarbital (120 mg kg 21 ).
Neurological scores and infarct volume
Neurological scores were evaluated using an 18-point scoring system reported by Garcia and colleagues 23 by a blinded observer. The final score given to each animal was the summation of all six individual test scores. Cerebral infarct volume was measured using 2,3,5-triphenyltetrazolium chloride (TTC) staining (Sigma-Aldrich) as described. 18 
Results
Characterization of differentiated SH-SY5Y cells
Expression of neuronal protein markers NeuN and bIII-tubulin was evaluated in RA-stimulated SH-SY5Y cells at various times during the differentiation process (Fig. 1A-C) . Expression of NeuN and bIII-tubulin was found at 1, 4, 7, and 10 days after RA stimulation (Fig. 1B and C) . The highest expression was observed at 7 days after stimulation. Immunofluorescent staining of 7 day RA-stimulated cells showed that the majority of the differentiated cells expressed NeuN and bIII-tubulin (Fig. 1D) . Therefore, RA-stimulated SH-SY5Y cells incubated for 7 days were used in subsequent experiments. The differentiated cells also expressed a considerable amount of TREK-1 protein. 
TREK-1 mediates sevoflurane neuroprotection
Sevoflurane preconditioning induced neuroprotection in vitro OGD reduced cell viability in differentiated SH-SY5Y cells, as evaluated by MTT and expression of Caspase-3. Preconditioning with sevoflurane (pre+OGD group) significantly attenuated the decrease in cell viability induced by OGD (P,0.05).
To clarify the role of TREK-1 in the neuroprotective effect of sevoflurane, siRNA knockdown was used (Fig. 2A) 
Sevoflurane preconditioning induced neuroprotection in vivo
We further evaluated the role of TREK-1 in the induction of the neuroprotection of sevoflurane preconditioning in a focal cerebral ischaemia animal model. Changes of physiological parameters during oxygen inhalation or sevoflurane preconditioning are shown in Table 1 . There were no significant differences among corresponding time points and between the sevoflurane and oxygen groups. Neuroprotection by sevoflurane preconditioning on ischaemia-reperfusion injury induced by MCAO was studied in the rat at 72 h and 1 week after reperfusion (Fig. 3) . Sevoflurane preconditioning significantly attenuated neurological deficits, as judged by assessment of neurological scores, at 24 h [10 (8,12) ], 48 h [9.25 (8,11) 
Sevoflurane preconditioning increased expression of TREK-1
Cerebral ischaemia -reperfusion injury, induced by MCAO, elevated expression of TREK-1 protein (Fig. 4A) and mRNA (Fig. 4B ) levels at 4, 24, and 48 h after ischaemia. The increased TREK-1 expression in sevoflurane preconditioning groups was significantly higher than that of the MCAO group (P,0.05, Pre+MCAO vs MCAO).
Knockdown of TREK-1 by siRNA attenuated sevoflurane preconditioning-induced neuroprotection (Fig. 5D ). Infarct volume examined at 72 h after ischaemia in this group was larger than that in the Pre+MCAO group [20 (6%) in the Pre+ MCAO group vs 39 (5%) in the SiRNA+Pre+MCAO group, P,0.05, Fig. 5B and C]. There was no detectable difference between the MCAO group and the siRNA+Pre+MCAO group (P.0.05).
Discussion
The role of TREK-1, a two-pore domain potassium channel, in the neuroprotective effect induced by sevoflurane preconditioning against ischaemic events was studied in vitro and in vivo. The main findings are: (i) sevoflurane preconditioning improved cell viability and reduced apoptosis in neurone-like differentiated SH-SY5Y human neuroblastoma cells challenged by OGD. (ii) Sevoflurane preconditioning improved neurological outcomes and reduced infarction volume in rats Table 1 Arterial blood gas anyalysis. Using separate animals, data for arterial blood gases were obtained before, during, and after 10 min of preconditioning in sevoflurane (Pre+MCAO) and oxygen control (MCAO) animals. There were no significant differences between the two groups. Values are expressed as mean (SEM), n¼5 in each group Transient, non-lethal ischaemic preconditioning is the most effective method to protect neurones from subsequent severe ischaemic injury in surgery. 25 Unfortunately, ischaemic preconditioning is invasive and therefore impractical for clinical practice. On the other hand, preconditioning using anaesthetic agents is less invasive and more amenable than preconditioning with ischaemia. Volatile anaesthetic agents such as sevoflurane and isoflurane can induce ischaemic tolerance to cerebral and spinal cord ischaemia in rabbits and rats. 26 -29 Repeated brief isoflurane anaesthesia induces focal cerebral ischaemia tolerance in rats in a dose -response manner. 29 In this study, we confirmed that sevoflurane preconditioning significantly attenuated OGD-induced cell injury in vitro and reduced infarct volume and improved neurological deficits induced by cerebral ischaemia -reperfusion injury in vivo in a transient ischaemia rat model. In clinical practice, sevoflurane preconditioning has been applied before coronary arterial surgery with evidence of cardioprotection. 30 Based on our findings, the neuroprotective effect of sevoflurane preconditioning in the perioperative period should be tested. The precise mechanisms underlying the improvement of neurological function and reduction in brain damage by volatile anaesthetic preconditioning remain undefined. Isoflurane can inhibit glutamate release and reduce excitatory postsynaptic glutamate receptor-mediated responses. 31 32 We have shown that volatile anaesthetic preconditioning induces neuroprotection by up-regulating antioxidant enzyme activities before ischaemic damage through generating reactive oxygen species. 27 Free radicals might contribute to the endogenous antioxidant system after anaesthetic preconditioning. Yang and colleagues 4 demonstrated that volatile anaesthetic preconditioning-induced protective effects against transient cerebral ischaemic injuries are mediated by activation of the Notch signalling pathway in mice. Ubiquitin-conjugated proteins also participate in cerebral ischaemic tolerance by isoflurane preconditioning. 28 Inhibition of glycogen synthase kinase 3b (GSK3b), activation of which can lead to cell death, might play a key role in volatile anaesthetic postconditioninginduced neuroprotection. 33 However, the relationships in the molecular network associated with the neuroprotective mechanism of volatile anaesthetics preconditioning are still unclear. Two-pore domain K + channels have received considerable attention in neuroprotection in recent years. TREK-1 is expressed throughout the brain and spinal cord and activated by membrane stretch, intracellular acidification, and lysophospholipids. 34 Lysophospholipids possess a potent protective effect against global cerebral ischaemia injury or glutamate excitotoxicity in neuronal cultures. 35 Since extracellular lysophospholipids open TREK-1 channels, it is likely that the K 2 P channels might also have a neuroprotective role. Heurteaux and colleagues 13 showed that TREK1 2/2 mice have increased TREK-1 mediates sevoflurane neuroprotection sensitivity to ischaemia and epilepsy. However, mice that lack TREK-1 expression did not show increased damage after traumatic brain injury. 36 These controversial results indicate that the role of TREK-1 in neuroprotection requires further investigation. TREK-1 is activated by a variety of volatile anaesthetics such as isoflurane, sevoflurane, and halothane in transfected mammalian cells. 37 However, other structurally and functionally different K 2 P channels, such as TRAAK, are insensitive to volatile anaesthetics. 38 Accumulated evidence supports that TREK-1 is activated by volatile anaesthesia agents. 39 We postulated that volatile anaesthetic preconditioning induces cerebral ischaemic tolerance through activation of TREK-1. The neuroprotective effect of sevoflurane preconditioning was partially reversed by down-regulation of TREK-1 with siRNA, as supported by the deleterious effect on neurological function and increases in infarct volume after MCAO. Sevoflurane preconditioning apparently activates TREK-1 in differentiated SH-SY5Y cells and rat brain, and leads to tolerance against ischaemia. These findings strengthen the idea that neuroprotection induced by sevoflurane preconditioning against ischaemia is related to its action on TREK-1 and open the way for a novel neuroprotective strategy. Nevertheless, the mechanism of neuroprotection by TREK-1 activation induced by volatile anaesthetics preconditioning needs to be further elucidated.
Westphalen and colleagues 40 found that deletion of TREK-1 significantly reduced the inhibitory effect of halothane on glutamate release from cerebrocortical nerve terminals, which implies that reduced excitatory transmission is a possible mechanism of neuroprotective effect of anaesthetic preconditioning. The intracellular signal transduction events after activation of TREK-1 by sevoflurane are still unclear.
In conclusion, preconditioning with sevoflurane protects neurones from ischaemic injury and this effect is affected by TREK-1. The mechanistic link between TREK-1 activation by sevoflurane and improved neurological outcome needs to be explored in further detail.
